



Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

August 28, 2024

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals International, plc](https://www.kiniksa.com) (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 8:00 a.m. Eastern Time.

A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets, ARCALYST[®], abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST[®] is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts![®]

Kiniksa Investor Contact

Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com

Kiniksa Media Contact

Tyler Gagnon
(781) 431-9100
tgagnon@kiniksa.com